SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-005849
Filing Date
2021-01-11
Accepted
2021-01-11 08:37:31
Documents
14
Period of Report
2021-01-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d105171d8k.htm   iXBRL 8-K 26977
2 EX-99.1 d105171dex991.htm EX-99.1 32289
6 GRAPHIC g105171g0110235448162.jpg GRAPHIC 3274
  Complete submission text file 0001193125-21-005849.txt   196783

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA alny-20210110.xsd EX-101.SCH 3066
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE alny-20210110_lab.xml EX-101.LAB 18138
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE alny-20210110_pre.xml EX-101.PRE 11405
7 EXTRACTED XBRL INSTANCE DOCUMENT d105171d8k_htm.xml XML 3387
Mailing Address 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MA 02142
Business Address 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MA 02142 (617) 551-8200
ALNYLAM PHARMACEUTICALS, INC. (Filer) CIK: 0001178670 (see all company filings)

IRS No.: 770602661 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36407 | Film No.: 21519414
SIC: 2834 Pharmaceutical Preparations